AAJ: Latest Medtronic Device Failure Highlights Dangers of Preemption

Text Size

AAJ: Latest Medtronic Device Failure Highlights Dangers of Preemption 

For Immediate Release: March 19, 2008

Contact: Cecelia Prewett
202.965.3500, x369

Washington, DC—A new Food and Drug Administration (FDA) public health notification shows a higher death rate after five years among patients treated for abdominal aortic aneurysm with Medtronic Inc.’s Aneu-Rx stent-graft system than among those treated through conventional surgery.

The recent U.S. Supreme Court ruling in Riegel v. Medtronic, Inc. limited the rights of people to receive justice through the legal system when harmed by medical devices such as Aneu-Rx.

The following is a statement from American Association for Justice VP of Strategic Communications Cecelia Prewett:

“This latest FDA announcement once again shows the dangers of preemption.

“Preemption eliminates accountability through the civil justice system. The Riegel decision destroys any incentive for Medtronic to make Aneu-Rx safer or more effective.

“State remedies are designed to complement, not conflict with, federal health and safety regulations. Congress should take the lead in ensuring federal regulatory agencies are following Congressional intent and not preempting state tort remedies.”

For a copy of AAJ's comments, please contact Communications at media.replies@justice.org or 202.965.3500, x369.

As the world's largest trial bar, the American Association for Justice (formerly known as the Association of Trial Lawyers of America) works to make sure people have a fair chance to receive justice through the legal system when they are injured by the negligence or misconduct of others—even when it means taking on the most powerful corporations. Visit http://www.justice.org/newsroom.

The American Association for Justice
777 6th Street, NW, Ste 200 • Washington, DC  20001 • 800.424.2725 or 202.965.3500

© 2014 AAJ